The total annual average cost per patient was 13,206 Ffr in the lithium group and 17,486 Ffr in the carbamazepine group.
The lithium group costs were 4,280 Ffr less than the carbamazepine group, (p=0.045).
The costs of adverse effects were included in the analysis.